View Press Releases
Italian Pharmaceutical Manufacturer and CMO, IBI Lorenzini, Selects TraceLink to Comply with Global Serialization Regulations
- Jun 27, 2018 -
North Reading, MA (June 26, 2018)-TraceLink Inc., the Worlds Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that IBI Lorenzini has selected TraceLinks solutions to ensure compliance with global serialization regulations.
IBI Lorenzini, IBIGEN group, is an Italian-based, family-run pharmaceutical company and contract manufacturing organization (CMO) that was founded over 100 years ago. IBIs pharmaceutical products are distributed in 20 countries across all five continents, including Europe, Australia and New Zealand, and the U.S., which accounts for 80% of its exports. In 1961, IBI obtained FDA approval for the production of sterile penicillin for the U.S. market.
IBI Lorenzini is a unique business, operating as both a pharmaceutical company and a CMO in a number of markets, which adds an additional layer of complexity when implementing a serialization solution. After careful analysis of serialization solutions and a strong recommendation from our pharmaceutical brand customers, we selected TraceLinks Life Sciences Cloud platform to deliver the flexibility and scalability we needed to connect with both our partners and customers as quickly and efficiently as possible, while providing a simple connection into the EU Hub. said Luca Pezzano, Operations Director at IBI Lorenzini.
For its U.S. Drug Supply Chain Security Act (DSCSA) requirements, IBI has completed all serialization packaging line upgrades and partner connections in the U.S. In preparation for EU Falsified Medicines Directive (FMD), IBI has started the integration process with its CMO partners, discussing data exchange processes and redesigning artwork to include tamper evidence. The company aims to be ready for FMD serialization by the end of 2018, ahead of the February 2019 deadline.
As a progressive company that consistently adopts innovative digital countermeasures to reduce the risks of falsified medicines and protect consumers health, IBI Lorenzini recognized the urgency of EU FMD and began preparations early on, in order to ensure compliance and improve patient safety. With the EU FMD deadline on the horizon, there is relatively little time left for companies to have new technologies and processes fully implemented and connected into the EU Hub, said Shabbir Dahod, president and CEO of TraceLink. TraceLink has a proven ability to simplify serialization challenges and we look forward to partnering with IBI Lorenzini to not only ensure EU FMD compliance but to explore and realize the wider potential of information sharing through digital network connectivity.
TraceLink has developed a streamlined program for its more than 190 customers with EU FMD requirements to rapidly complete conformance testing and successfully receive European Medicines Verification Organization (EMVO) approval to submit data to the EU Hub. With TraceLinks conformance test kit, 42 companies have been able to complete their conformance testing. Of these, 21 companies have received EMVO approval and seven companies are awaiting review from the EMVO.
About TraceLink
TraceLink is the Worlds Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloittes Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com or follow us on LinkedIn, Twitter and Facebook.
TraceLink is funded by Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital.
Media contacts:
Aimee Genzler
Senior Director, Corporate Communications
TraceLink
agenzler@tracelink.com
978.396.6150
Italian Pharmaceutical Manufacturer and CMO, IBI Lorenzini, Selects TraceLink to Comply with Global Serialization Regulations
North Reading, MA (June 26, 2018)-TraceLink Inc., the Worlds Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that IBI Lorenzini has selected TraceLinks solutions to ensure compliance with global serialization regulations.
IBI Lorenzini, IBIGEN group, is an Italian-based, family-run pharmaceutical company and contract manufacturing organization (CMO) that was founded over 100 years ago. IBIs pharmaceutical products are distributed in 20 countries across all five continents, including Europe, Australia and New Zealand, and the U.S., which accounts for 80% of its exports. In 1961, IBI obtained FDA approval for the production of sterile penicillin for the U.S. market.
IBI Lorenzini is a unique business, operating as both a pharmaceutical company and a CMO in a number of markets, which adds an additional layer of complexity when implementing a serialization solution. After careful analysis of serialization solutions and a strong recommendation from our pharmaceutical brand customers, we selected TraceLinks Life Sciences Cloud platform to deliver the flexibility and scalability we needed to connect with both our partners and customers as quickly and efficiently as possible, while providing a simple connection into the EU Hub. said Luca Pezzano, Operations Director at IBI Lorenzini.
For its U.S. Drug Supply Chain Security Act (DSCSA) requirements, IBI has completed all serialization packaging line upgrades and partner connections in the U.S. In preparation for EU Falsified Medicines Directive (FMD), IBI has started the integration process with its CMO partners, discussing data exchange processes and redesigning artwork to include tamper evidence. The company aims to be ready for FMD serialization by the end of 2018, ahead of the February 2019 deadline.
As a progressive company that consistently adopts innovative digital countermeasures to reduce the risks of falsified medicines and protect consumers health, IBI Lorenzini recognized the urgency of EU FMD and began preparations early on, in order to ensure compliance and improve patient safety. With the EU FMD deadline on the horizon, there is relatively little time left for companies to have new technologies and processes fully implemented and connected into the EU Hub, said Shabbir Dahod, president and CEO of TraceLink. TraceLink has a proven ability to simplify serialization challenges and we look forward to partnering with IBI Lorenzini to not only ensure EU FMD compliance but to explore and realize the wider potential of information sharing through digital network connectivity.
TraceLink has developed a streamlined program for its more than 190 customers with EU FMD requirements to rapidly complete conformance testing and successfully receive European Medicines Verification Organization (EMVO) approval to submit data to the EU Hub. With TraceLinks conformance test kit, 42 companies have been able to complete their conformance testing. Of these, 21 companies have received EMVO approval and seven companies are awaiting review from the EMVO.
About TraceLink
TraceLink is the Worlds Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloittes Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com or follow us on LinkedIn, Twitter and Facebook.
TraceLink is funded by Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital.
Media contacts:
Aimee Genzler
Senior Director, Corporate Communications
TraceLink
agenzler@tracelink.com
978.396.6150